Mode
Text Size
Log in / Sign up

5-ALA fluorescence-guided surgery improves gross total resection rates in patients with glioblastomaFluorescence guided surgery improves tumor removal for glioblastoma patients

AI-generated summary of the cited source, checked by automated accuracy review. How we work

Key Takeaway
Consider 5-ALA guided surgery to improve gross total resection rates without increasing neurological morbidity.

This meta-analysis evaluated the efficacy of 5-aminolevulinic acid (5-ALA) fluorescence-guided surgery compared to white-light microsurgery for patients with newly diagnosed glioblastoma. The analysis included a total sample size of 790 adults and focused on surgical outcomes, survival metrics, and neurological safety.

Key findings indicate that 5-ALA guided surgery significantly improved gross total resection (GTR) rates compared to white-light microsurgery (RR = 1.54; 95% CI: 1.16-2.04; p = 0.003). Mean overall survival was also significantly prolonged by 2.89 months (95% CI: 0.73-5.04; p = 0.009) in the 5-ALA group. However, there was no significant difference in overall survival at 12 months (RR = 1.31; 95% CI: 0.81-2.13; p = 0.27). Neurological morbidity rates were comparable between both surgical techniques.

The authors noted limitations including a lack of standardized definitions for extent of resection and progression-free survival across included studies, as well as the need for molecularly stratified cohorts. Clinically, 5-ALA guided surgery may enhance resection completeness without increasing neurological complications, potentially offering modest survival benefits in glioblastoma management.

How this fits prior evidence

This meta-analysis addresses a gap in surgical management for glioblastoma by evaluating 5-ALA fluorescence guidance. While previous coverage noted that 5-ALA PDT is an effective option for cervical squamous intraepithelial lesions to improve response rates and HPV clearance, this finding specifically addresses the role of 5-ALA in improving gross total resection (RR = 1.54) and mean overall survival (MD = 2.89 months) in glioblastoma patients.

When doctors treat glioblastoma, a common and aggressive brain cancer, the goal is to remove as much of the tumor as possible. This can be difficult because tumors often blend into healthy tissue. A review of data from 790 adults shows that using a substance called 5-ALA can help surgeons see the boundaries more clearly during surgery.

This technique, known as fluorescence guided surgery, significantly improved the rate of gross total resection. In plain terms, this means doctors were much better at removing the bulk of the tumor compared to using standard white light alone. Importantly, this extra visibility did not lead to more neurological problems for the patients, meaning it was just as safe as traditional methods.

While the average survival time increased by about 3 months, the results at the 12-month mark were not significantly different between the two groups. Because some studies used different ways to measure progress, the evidence is still evolving. However, the data suggests that this light guide helps surgeons be more thorough during a critical operation.

What this means for you:
Fluorescence guided surgery helps doctors remove more of a brain tumor without increasing risks for patients.

Study Details

Study typeMeta analysis
Sample sizen = 790
EvidenceLevel 1
Follow-up12.0 mo
PublishedJul 2026
View Original Abstract ↓
Glioblastoma (GBM) is the most common and aggressive primary malignant brain tumour in adults, characterized by diffuse infiltration and poor prognosis despite multimodal therapy. Maximal safe surgical resection remains the cornerstone of management, as greater extent of resection (EOR) correlates with improved survival. However, conventional white-light microscopy often fails to distinguish tumour margins from surrounding functional brain tissue. 5-aminolevulinic acid (5-ALA) fluorescence-guided surgery enhances intraoperative visualization by selectively accumulating protoporphyrin IX in tumour cells, allowing real-time delineation of malignant tissue. This systematic review and meta-analysis aimed to evaluate the efficacy and safety of 5-ALA-guided resection compared with conventional white-light microsurgery in adults with newly diagnosed GBM. The review was conducted in accordance with PRISMA and Cochrane guidelines, and prospectively registered on PROSPERO (CRD420251160699). Comprehensive searches of PubMed, Embase, Scopus, Cochrane Library, and Google Scholar were performed from inception to July 2025. Randomized controlled trials (RCTs) and non-randomized controlled trials (NRCTs) comparing 5-ALA-guided and white-light surgery were included. Two reviewers independently screened studies, extracted data, and assessed risk of bias using RoB 2.0 for RCTs and the Newcastle-Ottawa Scale for NRCTs. Meta-analyses were performed using random-effects models (RevMan 5.4), and outcomes were summarized as risk ratios (RRs) or mean differences (MDs) with 95% confidence intervals (CIs). Certainty of evidence was graded using GRADE methodology. Seven studies involving 790 patients (three RCTs, four NRCTs) were included. Pooled analysis demonstrated that 5-ALA-guided surgery significantly improved gross total resection (GTR) compared with white-light microsurgery (RR = 1.54; 95% CI: 1.16-2.04; p = 0.003). Although 12-month overall survival (OS) did not differ significantly (RR = 1.31; 95% CI: 0.81-2.13; p = 0.27), mean OS was significantly prolonged with 5-ALA (MD = 2.89 months; 95% CI: 0.73-5.04; p = 0.009). Neurological morbidity was comparable between groups (RR = 1.31; 95% CI: 0.81-2.13; p = 0.27). Systematic evidence further supported higher EOR and lower subtotal resection rates with 5-ALA. Functional outcomes and progression-free survival (PFS) were generally similar, though some studies indicated modest PFS benefit. Safety analyses showed a low incidence of treatment-related adverse events, with photosensitization being the most frequent; neurological complication rates and perioperative mortality were comparable. 5-ALA-guided fluorescence surgery significantly enhances resection completeness in newly diagnosed GBM without increasing neurological morbidity and may confer modest survival benefit. Its favourable safety profile and reproducible efficacy support its integration into standard neurosurgical protocols aimed at maximizing safe tumour removal. Future trials should incorporate molecularly stratified cohorts, standardized definitions of EOR and PFS, and long-term functional outcomes to identify patient subgroups deriving the greatest benefit.
Free Newsletter

Clinical research that matters. Delivered to your inbox.

Join thousands of clinicians and researchers. No spam, unsubscribe anytime.